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ABSTRACT
Cisplatin and derivatives are commonly used as chemotherapeutic
agents. Although the cytotoxic action of cisplatin on cancer cells is
very efficient, clinical oncologists need to deal with two major
difficulties, namely the onset of resistance to the drug and the
cytotoxic effect in patients. Here, we used Caenorhabditis elegans to
investigate factors influencing the response to cisplatin in multicellular
organisms. In this hermaphroditic model organism, we observed that
sperm failure is a major cause of cisplatin-induced infertility. RNA
sequencing data indicate that cisplatin triggers a systemic stress
response, in which DAF-16/FOXO and SKN-1/NRF2, two conserved
transcription factors, are key regulators. We determined that inhibition
of the DNA damage-induced apoptotic pathway does not confer
cisplatin protection to the animal. However, mutants for the pro-
apoptotic BH3-only gene ced-13 are sensitive to cisplatin, suggesting
a protective role of the intrinsic apoptotic pathway. Finally, we
demonstrated that our system can also be used to identify mutations
providing resistance to cisplatin and therefore potential biomarkers of
innate cisplatin-refractory patients. We show that mutants for the
redox regulator trxr-1, ortholog of the mammalian thioredoxin
reductase 1 TRXR1, display cisplatin resistance. By CRISPR/Cas9,
we determined that such resistance relies on the presence of the
single selenocysteine residue in TRXR-1.
This article has an associated First Person interview with the first
author of the paper.
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INTRODUCTION
The US Food and Drug Administration approved the use of cisplatin
[CDDP, cis-diammine-dichloroplatinum(II)] as a chemotherapeutic
agent in 1978. Since then, cisplatin and other platinum-based
derivatives have been used successfully in cancer treatment. To
illustrate their impact in the clinic, it has been estimated that
approximately half of all patients undergoing chemotherapeutic
treatment receive a platinum drug (Galanski, 2006). Cisplatin exerts
activity against a wide spectrum of solid neoplasms, including
testicular, bladder, ovarian, head and neck, gastric and lung cancers
(Dasari and Bernard Tchounwou, 2014). Strikingly, testicular
cancer was previously fatal, but treatment with cisplatin provided a
cure for 80% of the patients (Gonzalez-Exposito et al., 2016).
Despite its effectiveness, there are patients intrinsically resistant to
cisplatin-based therapies, and an important fraction of tumors
eventually develop chemoresistance (Amable, 2016).
Cisplatin is composed of a double-charged platinum ion
surrounded by four ligands, two amines and two chlorides. Inside
cells, the low chloride concentration facilitates cisplatin aquation,
replacing chloride groups by water molecules. This process produces
a hydrolyzed (or aquated) form of cisplatin that is a potent electrophile
(attracted to electrons) that can react with any nucleophile, including
nucleic acids and the sulfhydryl groups of proteins (Kelland, 2007).
Cisplatin activity has an impact in the nucleus and in the
cytoplasm. In the nucleus, cisplatin produces DNA intra- and
interstrand crosslinks that lead to apoptosis (Kelland, 2007). In the
cytoplasm, owing to its electrophilic activity, cisplatin behaves as an
oxidant (loss of electrons results in oxidation), binding to proteins,
including mitochondrial proteins, and especially to thiol groups
(-SH). Thus, cisplatin produces a reactive oxygen species
homeostasis imbalance that leads to more oxidizing conditions,
which violate normal cellular function and, ultimately, can also
promote apoptosis (Wang and Lippard, 2005). As a result of its
broad and unspecific mode of action, cisplatin also affects normal
cells. Nephrotoxicity, neurotoxicity and ototoxicity are some of the
dose-limiting side effects reported upon cisplatin therapy (Kelland,
2007). Nevertheless, the major obstacle for the clinical efficacy of
cisplatin as an anticancer drug is the chemoresistance developed by
tumors rather than its toxicity in normal cells.
The acquisition of cisplatin resistance is multifactorial. The
mechanisms by which tumor cells become resistant to the action of
cisplatin have been classified into three types (Galluzzi et al., 2014):
(1) pre-target mechanisms, i.e. reducing intracellular accumulation
of cisplatin or increasing sequestration of cisplatin by nucleophilic
scavengers as glutathione (GSH), metallothioneins and other
cysteine-rich proteins; (2) on-target mechanisms, i.e. acquiring the
ability to repair adducts or becoming tolerant to unrepaired DNA
lesions; and (3) post-target mechanisms, i.e. hampering the
execution of apoptosis in response to DNA damage (Siddik, 2003).Received 8 January 2018; Accepted 10 April 2018
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Caenorhabditis elegans is a well-established organism for the
study of signaling pathways in response to drug exposure (Kaletta
and Hengartner, 2006). Previous studies, performed in distinct
biological contexts (Hemmingsson et al., 2010; Collis et al., 2006),
have revealed the value of C. elegans to identify genes related to the
cisplatin response (Table S1). Here, we show, for the first time, that
cisplatin in C. elegans produces DNA adducts and a systemic
response driven by two conserved transcription factors. We have
uncovered a sperm-specific sensitivity to cisplatin and have
demonstrated that resistance of the nematode to cisplatin relies on
the presence of a single selenocystein of the thioredoxin reductase
TRXR-1. Thus, this report is a more comprehensive study of the
global response of C. elegans to cisplatin that also establishes a
reliable methodology for future studies on mechanisms of resistance
to cisplatin that would continue contributing to the search for new
targets and markers for the benefit of cisplatin-based therapies.
RESULTS
A reliable assay to study the effect of cisplatin in C. elegans
In C. elegans nematodes, cisplatin produces a wide variety of
phenotypes depending on the concentration, length of treatment and
developmental stage of the treated animals (Tables S1 and S2).
To implement a reliable methodology and systematically investigate
the response of C. elegans to cisplatin, we established dose–
response patterns during larval development, when cell divisions
occur in somatic and germ cells. We exposed a synchronized
population of L1 larvae on nematode growth medium (NGM) plates
to different cisplatin concentrations for 96 h. We observed effects
ranging from a developmental delay at 50 µg/ml to a larval arrest at
200 µg/ml (Fig. 1A). Based on this assay, we concluded that body
length at 48 h post-L1, upon cisplatin exposure from 50 to 75 µg/ml,
is a reliable indicator of the effect of cisplatin during C. elegans
development (Fig. 1B). Thus, we established a methodology to
investigate how distinct treatments or gene activities can influence
the response of C. elegans to cisplatin.
Transcriptional response of C. elegans to cisplatin
To explore the global response of nematodes to cisplatin, we studied
transcriptional signatures in RNA sequencing (RNA-seq)
experiments. We performed this new transcriptome analysis using
a mixed-stage nematode population that was treated for 24 h with
60 µg/ml of cisplatin, because this dosage of cisplatin produces
some phenotypes, but does not compromise the viability of the
animals. To reduce the number of false positives, we used two
Fig. 1. Dose–response effect of
cisplatin on C. elegans development
and RNA-seq of animals exposed
to cisplatin. (A) Effect of distinct
concentrations of cisplatin on larval
development. Synchronized L1 larvae
were grown on agar plates and exposed to
different doses of cisplatin for 96 h at
20°C. Body length values represent mean
and SD (n=50) of two different
experiments. (B) Body length of
nematodes that were grown from L1
stage exposed to different doses of
cisplatin for 48 h at 20°C. Bars represent
mean and SD of three independent
replicates (n=50, N=3). (C) Schematic
representation of transcriptomic analyses.
Wild-type C. elegans from mixed stages
were cultured with and without cisplatin
(60 µg/ml) for 24 h at 20°C. Then, total
mRNA of two biological replicates was
purified and sequenced. Volcano plot
represents genes significantly up- and
downregulated (P<0.01) in cisplatin-
treated versus untreated animals.
(D) Color code represents the functional
categories of up- or downregulated genes.
Genes were clustered according to the
gene functional classification tool DAVID
and GO terms retrieved from WormBase.
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biological replicates to compare the transcriptomes of treated and
non-treated populations (Fig. 1C). We used the Cufflinks algorithm
(Trapnell et al., 2012) to process the RNA sequencing data and
study differential expression of genes. We identified a set of 83
genes upregulated and 78 genes downregulated by cisplatin in both
experiments (P≤0.05; Table S3). A more restricted list of
candidates, using a cut-off P-value of ≤0.01, included 28 genes
upregulated and 29 downregulated upon cisplatin exposure.
To explore the functions of these 57 genes, we performed a gene
ontology (GO) analysis and identified predicted protein domains
(COG) (Tatusov et al., 2003; Huang et al., 2009) (Fig. 1D). Genes
encoding CUB-like domains, C-type lectins and glutathione-S-
transferases were found among the genes upregulated upon cisplatin
exposure. In C. elegans, the expression of such genes is associated
with detoxification, redox balance, stress response and innate
immune system, and it is often regulated by the transcription factors
DAF-16 and SKN-1 (Singh and Aballay, 2009; Park et al., 2009;
Yen et al., 2011; Tepper et al., 2013) (Table S4).We also detected an
overlap with genes induced upon ionizing radiation (IR) (Greiss
et al., 2008; Schumacher et al., 2005a,b) (Table S4). Among those,
we found genes involved in the apoptotic signaling cascade,
including egl-1 and ced-13 (Greiss et al., 2008). However, as
described below, these two genes function in a distinct manner upon
cisplatin exposure.
Of the 29 genes downregulated by cisplatin, we found that most
of those were sperm-specific genes (Ortiz et al., 2014), with the
Major Sperm Protein (MSP) domain as the most frequent GO
annotation (Table S5). Therefore, the reduced brood size induced by
cisplatin might be provoked, at least in part, by a specific effect of
this agent on spermatogenesis and/or on sperm activity.
Cisplatin reduces the germ cell pool and affects sperm
functionality
Our transcriptome analyses indicated that male germline genes are
particularly downregulated in the presence of cisplatin. To
investigate the effect of cisplatin on the germline, we exposed L4
animals to cisplatin for 24 h, because the switch from
spermatogenesis to oogenesis occurs at this stage and therefore
both processes can be affected (Ellis and Schedl, 2007). As
expected, we observed a dose-dependent reduction of the brood
size upon cisplatin exposure (Meier et al., 2014) (Fig. 2A). This
reduction was correlated with an increase in the number of
unfertilized eggs laid (Fig. 2A) and a decrease in the number of
cells at the proliferative region of the germline (Fig. 2B). We
observed that cisplatin-treated germlines displayed fewer nuclei in
the mitotic region that appeared to be bigger (Fig. 2C), which is an
effect described in germlines exposed to DNA-damaging agents
that is attributable to cell cycle arrest upon activation of the S-phase
checkpoint (Gartner et al., 2004).
The increased number of unfertilized oocytes is a phenotypic
hallmark of sperm failure in C. elegans (Kadandale and Singson,
2004). To investigate whether the unfertilized oocytes observed
upon cisplatin treatment were the result of defective sperm, we
crossed cisplatin-treated hermaphrodites with untreated males. We
observed that sperm from untreated males rescued, at least in part,
the brood size and abrogated the presence of unfertilized oocytes
(Fig. 2D). These results suggest that the excess of unfertilized
oocytes is attributable to the effect of cisplatin in spermatogenesis
rather than in oogenesis.
To investigate the effect of cisplatin on sperm functionality, we
used the female/male strain fog-2(oz40), allowing the treatment of
males and females independently before the cross. fog-2(oz40)
females exposed to cisplatin and crossed with fog-2(oz40) untreated
males showed a reduced brood size, as expected from the effect of
cisplatin on mitotic cells, but we did not detect an increased
production of unfertilized oocytes (Fig. 2E). On the contrary, by
crossing fog-2(oz40) males exposed to cisplatin with untreated
fog-2(oz40) females we observed a stronger reduction of the
progeny, but also a higher number of unfertilized oocytes. These
results confirm that, at a similar dose, cisplatin does not hamper the
capacity of oocytes to be fertilized but affects the capability of sperm
to fertilize.
In summary, the exposure to cisplatin produces smaller germlines
as consequence of a reduction of the proliferative region and
fertilization problems caused by the effect of cisplatin in the sperm
(Fig. 2F).
DAF-16 and SKN-1 are key players in the response to
cisplatin
The abundance of dod (downstream-of-daf-16) genes and other
stress response genes in the list of genes upregulated upon cisplatin
exposure led us to study the role of DAF-16 and SKN-1. These are
the orthologs of human FOXO3 and NRF2, respectively, and are
required for stress resistance in C. elegans (Rodriguez et al., 2013).
Strikingly, we found that half of the upregulated genes were
previously reported as DAF-16 and/or SKN-1 targets (Fig. 3A).
The evolutionarily conserved insulin/insulin-like growth factor
signaling (IIS) pathway, through its main transcription factor DAF-
16/FOXO, controls many different biological processes and
regulates a wide variety of stresses, including starvation, oxidative
stress (Honda and Honda, 1999), heavy metal toxicity (Barsyte
et al., 2001) and ultraviolet radiation (Murakami and Johnson,
1996). DAF-16 is constitutively expressed and sequestered in
the cytoplasm in its phosphorylated form. If the inhibitory
phosphorylation is compromised, e.g. by reduced signaling of the
DAF-2 receptor tyrosine kinase or stress conditions, DAF-16 will
translocate to the nucleus. Using a DAF-16::GFP reporter strain, we
observed that DAF-16 nuclear location increased upon cisplatin
exposure in a dose-dependent manner (Fig. 3B), confirming the
implication of the IIS pathway in the response to cisplatin.
Next, we investigated the extent to which the manipulation of the
IIS activity could modify the response of the organism to cisplatin.
We observed that daf-2(e1370) mutants, which are animals lacking
a functional DAF-2/IGF-1-like receptor that constitutively induce
DAF-16 nuclear localization (Yen et al., 2011), display resistance to
cisplatin during larval development (Fig. 3C). Consistently, daf-
16(mu86) mutants were hypersensitive to cisplatin (Fig. 3C),
highlighting the relevance of DAF-16 nuclear activity in the cellular
response to cisplatin.
Differently from daf-2 and daf-16, skn-1 is an essential gene
hampering the use of loss-of-function mutants. To confirm the
implication of SKN-1 in the response to cisplatin, we used a GFP
reporter for one of its canonical targets, gst-4. SKN-1 regulates the
stress-induced gst-4 transcription in the presence of redox active
compounds, such as paraquat or heavy metals (Tawe et al., 1998;
Roh et al., 2006). In our RNA-seq data, gst-4 is one of the SKN-1-
regulated genes strongly induced by cisplatin, and we validated this
result using a gst-4 transcriptional GFP reporter (Fig. 3D,E).
Moreover, using skn-1 RNA interference (RNAi) we confirmed that
the cisplatin induction of gst-4 expression was skn-1 dependent and
daf-16 independent (Fig. 3D,E). Thus, by studying the impact of
cisplatin in the global gene expression we uncovered a systemic
response of the organism that is driven by two conserved
transcription factors. The fact that these transcription factors are
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effectors of metabolic and environmental signals opens new
avenues to regulate the response to cisplatin in multicellular
organisms.
The BH3-only protein CED-13 protects against cisplatin
We demonstrate, for the first time, that cisplatin leads to the
formation of DNA adducts in C. elegans (Fig. 4A) and induces
the expression of two apoptosis-related genes, egl-1 and ced-13,
which encode BH3-only proteins, which are a subset of the Bcl-2
familiy that contain only a BH3 domain and promote apoptosis.
egl-1 and ced-13 are transcriptionally induced upon DNA damage
(also upon exposure to UV or IR; Stergiou et al., 2007), and this
induction is CEP-1/P53 dependent (Greiss et al., 2008). Y47G7B.2,
another cisplatin-induced gene in our RNA-seq, encodes a
nematode-specific gene that is also upregulated upon DNA
damage in a cep-1-dependent manner (Greiss et al., 2008). Thus,
the effects of cisplatin on upregulation of apoptotic genes could be
attributable to cep-1-dependent DNA damage.
egl-1 is required for DNA damage-induced apoptosis in both
somatic tissues and the germline (Gartner et al., 2000). We
investigated egl-1 induction upon cisplatin exposure in the
soma using a GFP reporter strain (egl-1p::GFP). During larval
development, only 18 somatic cells of wild-type nematodes
undergo apoptosis at the early L2 stage (Lettre and Hengartner,
2006). Strikingly, a 24 h cisplatin treatment in C. elegans (from L1
to L2) induced ectopic egl-1p::GFP expression that was evident in
somatic cells (Fig. 4B,C). Moreover, this cisplatin-induced egl-1
ectopic expression was, at least in part, cep-1 dependent (Fig. 4D).
In the canonical DNA damage-induced apoptotic pathway, cep-1
is upstream of the BH3-only proteins EGL-1 and CED-13.
However, ced-13, and its downstream gene ced-3, have an
additional role in the intrinsic apoptotic pathway that promotes
Fig. 2. Effect of cisplatin in the germline. (A) Cisplatin reduces brood size and increases the percentage of unfertilized oocytes laid. L4 animals were exposed to
cisplatin for 24 h at the indicated concentrations (n=12, N=2). (B) Cisplatin reduces the number of germ cells in the proliferative region of C. elegans germline.
Number of cells corresponds to nuclei observed, in a single z-stack, at the proliferative region (50 μm away from the distal end of the gonad) (n=15, N=2).
(C) Representative DAPI staining of young adult germline exposed to cisplatin for 24 h. Right panels show magnification of the germline proliferative region
(highlighted area). (D) Impact of cisplatin on fertilization. Cisplatin produces unfertilized oocytes and causes reduced brood size in self-fertilized hermaphrodite
worms (‘Self’), but this effect is rescued, in part, by crossing cisplatin-treatedhermaphroditeswith untreatedmales (‘Cross’;n=12,N=2). ***P>0.001, **P>0.01, *P>0.1;
n.s., non-significant. (E) Cisplatin-induced unfertilized oocytes are caused by defective sperm. fog-2(oz40) hermaphrodites do not produce sperm, and mating is
necessary tomaintain the strain. Cisplatin produces unfertilized oocytes onlywhenmales are treated (n=12,N=2). ++P>0.01, +P>0.1 comparedwith female treatment
in the same conditions. (F) Schematic diagram to illustrate the effect of cisplatin in the germline: bigger nuclei at the proliferative zone (light blue), defective sperm
(red dots) and unfertilized oocytes (blue arrow). Bars show mean and s.e.m., and Student’s t-test was applied.
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protective changes rather than killing damaged irreparable cells
(Yee et al., 2014). Accordingly, we found that ced-13 and ced-3
mutants were sensitive to cisplatin, whereas two different cep-1
mutants were not resistant to cisplatin (Fig. 4E,F).
In summary, during C. elegans larval development, cisplatin
induces the expression of egl-1 and ced-13, but their influence is
distinct. Inhibition of the canonical DNA damage-induced apoptotic
pathway by using cep-1 mutants does not produce animals resistant
to cisplatin. On the contrary, ced-13 and ced-3mutants are sensitive
to cisplatin, underscoring a protective role of the intrinsic apoptotic
pathway upon cisplatin exposure in somatic cells.
TRXR-1 activity confers systemic sensitivity to cisplatin
The majority of C. elegans genes related to cisplatin response
published to date present cisplatin sensitivity if inactivated by RNAi
or mutation (Table S1). The human orthologs of these genes are
potential targets of therapies to re-sensitize cisplatin-resistant
tumors. Given the clinical importance of identifying refractory
patients, we wondered whether our system was also valuable for the
study of genes whose inactivation confers resistance to cisplatin. In
the clinic, mutations or single nucleotide polymorphisms in these
genes could function as predictive markers of cisplatin response. In
human cell lines, thioredoxin reductase 1 (TRXR1, also known as
TXNRD1) selenocysteine amino acid is a direct target of cisplatin,
producing cytotoxic and highly pro-oxidant TRXR1 forms called
SecTRAPs, which lead to high redox stress resulting in cell death
(Anestål et al., 2008). TRXR1 is one of the few selenoproteins
[proteins that include a selenocysteine (SeCys) amino acid] in
mammals, but TRXR-1 is the only selenoprotein in C. elegans (Li
et al., 2012) and, in contrast to mammals, this protein is not essential
Fig. 3. Role of DAF-16/FOXO and SKN-
1/Nrf2 transcription factors in the
response to cisplatin. (A) Venn
diagrams showing the significant overlap
between the genes induced by cisplatin
found in our transcriptomic analyses and
genes regulated by DAF-16 (Tepper et al.,
2013) and SKN-1 (Oliveira et al., 2009).
P<0.001 by Fisher’s test. (B) Cisplatin
induces DAF-16 nuclear translocation.
Representative image of L2 larvae
carrying a translational GFP reporter of
DAF-16 with and without cisplatin
(90 µg/ml for 5 h). The graph represents
the percentage of synchronized L2 larvae
with DAF-16::GFP predominantly nuclear
after 5 h of exposure to cisplatin at the
indicated concentrations. Bars represent
mean and s.e.m. (n=50, N=3). **P<0.01
relative to untreated worms by Student’s
t-test. (C) IIS pathway influences the
response to cisplatin. Body length of
synchronized L1 larvae grown for 4 days in
the absence or presence of cisplatin.
Worms were grown at 15°C to avoid daf-
2(e1370) dauer phenotype. The
inactivation of the IIS pathway in daf-
2(e1370) mutants, which keeps DAF-16
constitutively in the nucleus, causes
resistance to cisplatin, whereas the daf-
16(mu86) null mutant increases cisplatin
sensitivity. Translesion synthesis
polymerase 1 mutant allele polh-1(if31)
was used as a positive control (Roerink
et al., 2012). Bars represent mean and SD
(n=50). ***P<0.001 relative to untreated
worms by Student’s t-test. (D) Cisplatin-
induced activation of gst-4 is regulated by
SKN-1. Representative images of
synchronized gst-4p::GFP L4/young adult
animals grown at 20°C on daf-16(RNAi)
or skn-1(RNAi) bacteria from the L1 stage
in the presence or absence of cisplatin.
skn-1(RNAi) inhibits the cisplatin-induced
gst-4 expression. Worms fed with gfp
RNAi were used as a positive control.
(E) Fluorescence intensity for each
condition. Bars represent the mean. Error
bars indicate the s.e.m. (n=30, N=2).
***P<0.001 relative to untreated animals
by Student’s t-test.
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for viability (Stenvall et al., 2011). Depletion of C. elegans trxr-1
does not produce phenotypes in terms of morphology, growth,
lifespan, brood size or response to oxidative stress. It is essential
only for larval molting when the glutathione reductase gene gsr-1 is
inactivated in parallel (Stenvall et al., 2011). All these features
make C. elegans an excellent multicellular system in which to
study specifically the role of the SeCys residue in the response
to cisplatin.
Fig. 4. Role of apoptotic pathways in the response of C. elegans to cisplatin. (A) Southern blot showing that 1,2-GpG-intrastrand crosslinks are raised upon
cisplatin exposure of a C. elegans population. There is a dose-dependent accumulation of DNA adducts in the presence of cisplatin. NRK-52E rat cells, in which
1,2-GpG-intrastrand crosslinks are not present (Krüger et al., 2016), were incubated with cisplatin as a positive control. (B) Cisplatin induces egl-1 ectopic
expression in somatic tissues during larval development. Representative images of L2 worms carrying a egl-1p::GFP reporter, untreated and treated with cisplatin
(60 µg/ml for 24 h at 20°C). (C) Quantification of worms with ectopic egl-1p::GFP fluorescence in somatic cells of synchronized L1 larvae grown at the indicated
concentrations of cisplatin for 24 h at 20°C. Bars represent mean and s.e.m. of three different experiments (n=50). **P<0.01 by Student’s t-test. (D) egl-1 ectopic
induction in somatic cells requires cep-1/p53. Quantification of cells with ectopic egl-1p::GFP fluorescence of L1 larvae exposed to 60 µg/ml of cisplatin for
24 h at 20°C in wild-type and cep-1(gk138) mutants. Bars represent mean and s.e.m. of three different experiments (n=50). ***P<0.01 by Student’s t-test.
(E,F) Inactivation of the cep-1/p53 apoptotic pathway does not increase cisplatin resistance. (E) Body length of L1 larvae of wild-type and distinct mutant alleles
grown in cisplatin (60 µg/ml) for 48 h at 20°C. Bars represent mean and s.d. (n=50). This experiment was performed three times with similar results. (F) Relative
values of growth delay were obtained by calculating the percentage of the difference in the body length before and after cisplatin exposure (non-parametric
Kruskal–Wallis test, ***P<0.001; *P< 0.05; n.s., non-significant).
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We tested the robustness of our model by studying the role of
thioredoxin reductase 1 (trxr-1) in the C. elegans response to cisplatin.
We used the CRISPR/Cas9 system to produce two endogenous
TRXR-1 variants, trxr-1(cer4[U666C]) and trxr-1(cer5[U666STOP]),
that change the selenocysteine for cysteine and a STOP codon,
respectively (Fig. 5A). In a similar manner to the null mutant trxr-
1(sv47), these missense mutations showed larval arrest, attributable to
molting defects, in combinationwith gsr-1(RNAi) (Fig. 5B). Strikingly,
both the null mutant and the point mutations without the selenocysteine
produce resistance to cisplatin (Fig. 5C). Thus, both the developmental
function and the capacity to promote cytotoxicity in the presence of
cisplatin rely on the presence of the selenocysteine residue.
Therefore, the electrophilic activity of hydrolyzed cisplatin in the
presence of selenocysteine might produce cytotoxic SecTRAP
forms that are major drivers of the harmful effect of cisplatin on
multicellular organisms (Fig. 5D).
We also explored the role of trxr-1 in sensitizing the animal to
cisplatin. We found that trxr-1(sv47) confers resistance in germ cells
and in somatic cells. Interestingly, by combining trxr-1(sv47) with
daf-2 and daf-16mutations, the IIS pathway is epistatic to the trxr-1
activity on cisplatin resistance (Fig. S1).
DISCUSSION
Despite three decades of clinical use and intense research, greater
knowledge is necessary to understand, and ultimately control, the
molecular events driving endogenous and acquired resistance to
platinum-based chemotherapy (Dilruba and Kalayda, 2016). In this
context, model organisms are platforms with growing interest in
the study of the molecular, cellular and systemic responses to
chemotherapeutic agents, but also to screen for new treatments
(Nijman, 2015). Here, we reinforce the use ofC. elegans to study the
complex response of multicellular organisms to cisplatin. The
function of C. elegans genes in the response to cisplatin has been
shown in different biological contexts as adult survival or germline
apoptosis (Table S1). After testing some of these contexts, we
selected the body length of developmental larvae as a reliable and
Fig. 5. trxr-1 null and missense mutants are resistant to cisplatin. (A) Representation of the trxr-1 gene. Blue boxes represent exons, and lines
represent introns. The upper line denotes the 1663 bp region deleted in the sv47 allele. Selenocysteine codon TGA is the third last residue and is represented as
Sec. The wild-type sequence of the last four codons and their corresponding amino acids are boxed below. cer4[U666C] and cer5[U666STOP] Sec-deficient
trxr-1 mutant alleles, edited by CRISPR/Cas9, carry a single substitution in Sec codon (C instead of A or A instead of G) that changes the selenocysteine to
cysteine or a premature STOP codon, respectively. (B) Sec-deficient cer4[U666C] and cer5[U666STOP] alleles, in a similar manner to the trxr-1 null allele, cause
a molting-associated growth arrest when fed with gsr-1(RNAi).Graph shows the quantification of larval arrest of L1 larvae fed with gsr-1(RNAi) or control bacteria
(empty vector). Bars represent mean and s.d. (n=50, N=2). (C) trxr-1(sv47) null mutant and cer4[U666C] and cer5[U666STOP] point mutant strains show
increased resistance to cisplatin. Body length quantification of synchronized L1 larvae grown on agar plates containing 0 and 60 µg/ml of cisplatin for 48 h at 20°C.
Bars represent mean and s.d. (n=50). This experiment was performed in triplicate with similar results. ***P<0.001 relative to wild-type worms in the same
conditions by Student’s t-test. (D) Schematic diagram of the cytotoxic effect produced by the electrophilic activity of cisplatin when reacting with a selonocystein
present in thioredoxin reductase 1.
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scalable system to evaluate the response of the animal to cisplatin.
Nematodes are easy to synchronize at the L1 stage, and therefore we
can study homogeneous populations during larval development,
when somatic and germ cells are in active proliferation and
apoptotic pathways functional.
The C. elegans germline is diverse in cell types, because it
contains mitotic cells, meiotic cells, mature oocytes and sperm. We
observed that the effect of cisplatin on fertility and cell cycle arrest
in the mitotic germline is similar to that produced by other DNA-
damaging insults, such as ionizing or ultraviolet C radiations
(Gartner et al., 2004), suggesting a direct action of cisplatin on DNA
that is supported by our southwestern blots for DNA adducts (1,2-
GpG-intrastrand crosslinks). This cisplatin-induced DNA damage
response (DDR) in the C. elegans germline has already been
documented (van Haaften et al., 2006; Meier et al., 2014; Honnen,
2017). In addition, however, we found that defective sperm is a
major cause of the reduced C. elegans fertility observed upon
cisplatin exposure at L4. At this stage, we hit oogenesis only
partially, but our experiments with fog-2mutants suggest that sperm
and oocytes are different in terms of resistance to cisplatin.
Interestingly, cisplatin is particularly efficient for testicular tumors
and causes a drastic effect on spermatogenesis and sperm in treated
patients, but this harmful effect seems to affect primarily the
chromatin and is reversible (Bujan et al., 2013). In females with
ovarian cancer, cisplatin also affects gametogenesis, producing a
reduction of the ovarian reserve (Chang et al., 2015). Detailed
experiments need to be performed to gain a better understanding of
the step at which gametogenesis is hampered in the presence of
cisplatin. In this sense, the hermaphrodite condition of C. elegans is
a clear advantage to study the effect of any given cisplatin dose on
oogenesis and spermatogenesis in the same organism.
Our RNA-seq analyses revealed a transcriptomic signature in
the presence of cisplatin. The cisplatin-responsive genes identified
could be involved in cell autonomous mechanisms (cells have an
individual response to cisplatin uptake) or in non-cell autonomous
mechanisms (the effect in certain cells influences distant cells).
Given that DNA is damaged by cisplatin, a cell-autonomous
response occurs as a checkpoint mechanism to favor DNA repair
(Gartner et al., 2004). Nevertheless, the vast majority of genes
induced by cisplatin in our experiments are related to general stress
responses and the innate immune system, which suggests a
coordinated systemic response. According to the deregulated
genes, this response has DAF-16 and SKN-1 as major drivers and
has similarities to that obtained from nematodes exposed to IR or
UV-C (Boyd et al., 2010; Greiss et al., 2008). DAF-16 activation
positively regulates a wider spectrum of processes, such as stress
resistance, innate immunity and metabolic adaptation (Singh and
Aballay, 2009; Murphy and Hu, 2013), whereas the NRF2 C.
elegans ortholog SKN-1 is an important factor in detoxification
and response to oxidative stress, and its downregulation has been
associated with hypersensitivity to different stressor agents
(Blackwell et al., 2015).
Interestingly, immune and stress reactions upon DNA damage are
common in mammals (Ermolaeva and Schumacher, 2013), and
similar to what we observed in C. elegans, cisplatin induces the
nuclear translocation of the DAF-16 homolog FOXO3 (Fernandez
deMattos et al., 2008). Human FOXO proteins are crucial regulators
of a multitude of cellular functions (Yang and Hung, 2009), but our
results encourage further exploration of the manipulation of the IIS
pathway to control the cellular response to cisplatin.
The SKN-1 human ortholog NRF2 regulates the expression of
stress-responsive genes, such as SOD and catalases, or phase II
detoxification enzymes, such as glutathione transferases (Kaspar
et al., 2009). NRF2 overexpression or hyperactivation provokes a
direct effect in acquisition of resistance to a wide spectrum of
anticancer drugs in many cancer types (Gañán-Gómez et al., 2013;
Kaspar et al., 2009). Accordingly, increased nuclear NRF2
expression has been shown in cisplatin-resistant human bladder
cancer samples (Hayden et al., 2014). On the contrary, inhibition of
NRF2 sensitizes cisplatin-resistant A549 cells (Hou et al., 2015).
These observations are concordant with our findings in C. elegans,
suggesting that direct or indirect targeting of NRF2 should be
explored for cisplatin-combined therapeutic interventions.
Our transcriptomic analyses uncovered the upregulation of egl-1
and ced-13, which are related to apoptosis. Using a egl-1p::GFP
reporter, we found ectopic expression in somatic cells. The apoptotic
pathway in postembryonic somatic cells is not well described and
might be different in each somatic cell type. In the canonical view of
the DNA damage-induced apoptotic pathway, expression of the
effector EGL-1 marks cells destined to die (Nehme and Conradt,
2008), and cep-1/p53 is upstream (Schumacher et al., 2005a).
However, egl-1p::GFP is still overexpressed in cep-1/p53 mutants
exposed to cisplatin, indicating that inhibition of the DNA damage-
induced apoptotic pathway does not completely protect the animal
from cisplatin toxicity. Likewise, blockade of apoptosis in adult
worms through cep-1/p53 inhibition does not have any effect on
cisplatin sensitivity (Hemmingsson et al., 2010). Thus, inhibition of
the DNA damage-induced apoptotic pathway is not an efficient
strategy for animals to hamper the global effect of cisplatin.
Nonetheless, expression of cep-1/p53 seems to be important for the
full response to cisplatin, and p53 is required for the cytotoxic effect
of cisplatin in human glioblastoma cells (Park et al., 2006).
Surprisingly, we found that ced-13 upregulation might have a
protective role, because ced-13 mutants are sensitive to cisplatin.
Mutants of ced-3, a gene that is genetically downstream, are also
sensitive to cisplatin. This result fits with the role of ced-13 in the
mitochondrial intrinsic apoptotic pathway that extends C. elegans
longevity (Yee et al., 2014). It is possible that postmitotic cells,
which are irreplaceable, activate ced-13 activity to protect themselves
from cisplatin. The role of ced-13 might be dependent on the insult
levels or vary in distinct cell types, because overexpression of ced-13
in the soma induces cell death of somatic cells that normally survive
(Schumacher et al., 2005a). In concordance with a protective role for
ced-13 and ced-3, the activity of these genes appears to protect
dopaminergic neurons from the toxicity of an oxidative stress-
inducing drug (Offenburger et al., 2018).
Thioredoxin system proteins are key players in many important
cellular processes, including the maintenance of redox homeostasis
(Arnér, 2009; Lu and Holmgren, 2014). Regarding the influence of
thioredoxins in the cellular response to cisplatin, in mammalian
cells it has been shown that a delicate balance exists between the
cytotoxic effect of the direct interaction with cisplatin and the
protective effect, maintaining the redox equilibrium (Anestål et al.,
2008; Cebula et al., 2015). Studies in cell lines suggest that
cisplatin cytotoxicity is promoted by a direct interaction between
cisplatin and selenocysteine amino acids, leading to the consequent
formation of SecTRAPs (Anestål et al., 2008). We confirmed the
cisplatin-induced cytotoxicity of TRXR-1 and, generating two
distinct missense mutations by CRISPR/Cas9, we demonstrated
that this cytotoxicity relies on the presence of a single
selenocystein (Sec) at the C-terminal of the protein. Interestingly,
the presence of Cys instead of Sec in TRXR1 can be modulated by
the presence of the micronutrient selenium in the diet of rats
(Lu et al., 2009).
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The multifactorial nature of cisplatin resistance hampers the
finding of a unique solution to overcome the resistance of tumors to
cisplatin. However, there are many parallels between the response
of C. elegans and mammals to a cisplatin treatment that would
facilitate the study in nematodes of particular genetic, metabolic and
environmental factors influencing the resistance to cisplatin. This
information would be of great help to identify predictive biomarkers
and investigate new drugs to have more effective and personalized
cisplatin-based therapies.
MATERIALS AND METHODS
Nematode strains and general methods
Caenorhabditis elegans strains were cultured andmaintained using standard
procedures (Porta-de-la-Riva et al., 2012; Stiernagle, 2006). The N2
(Bristol) strain was used as wild-type in all experiments, and the following
alleles and transgenic strains were used in this study: BS553, fog-2(oz40) V;
XF132, polh-1(if31) III; CB1370, daf-2(e1370) III; TJ1, cep-1(gk138) I;
CE1255, cep-1(ep347) I; FX536, ced-13(tm536) X; MD792, ced-13(sv32)
X; VB1414, trxr-1(sv47) IV; CER170, trxr-1(cer4[U666C]) IV; CER171,
trxr-1(cer5[U666stop]) IV; CF1038, daf-16(mu86) I; TJ356, zIs356
[daf-16p::daf-16a/b::GFP + rol-6(su1006)] IV; WS1973, opIs56 [egl-
1p::2xNLS::GFP]; CER192, cep-1(gk138) I, opIs56(egl-1p::GFP); and
CL2166, dvIs19 [pAF15(gst-4p::GFP::NLS)] III.
CRISPR/Cas9
To generate the trxr-1(cer4[U666C]) and trxr-1(cer5[U666Stop]) point
mutation alleles, we targeted a site near the selenocysteine codon with
CRISPR/Cas9. To make the sgRNA expression plasmid, we cloned the
annealed oligonucleotides into BsaI-digested U6::sgRNA pMB70
(Waaijers et al., 2013). Repair templates containing desired modifications
were designed by Gibson Assembly Cloning Kit (New England BioLabs)
and cloned into the pBSK plasmid (Addgene). Oligonucleotide sequences
used to generate the 5′ and 3′ 1.5 kb overlapping fragments are available on
request. Both sgRNA and repair template were verified by sequencing using
T4 and M13 primers, respectively. Young adult wild-type animals were
injected with 30 ng/μl of sgRNA, 100 ng/μl of repair template, 30 ng/μl of
Peft-3::Cas9 vector (Friedland et al., 2013) and 2.5 ng/μl of Pmyo-2::
tdTomato. Single fluorescent progeny were isolated and screened for the
presence of the mutation by PCR. We finally established and validated
homozygous mutant lines by PCR and sequencing.
RNA-sequencing analyses
A mixed population of worms representing all stages and grown in control
conditions was exposed to 60 µg/ml of cisplatin. After 24 h at 20°C,
cisplatin-treated worms and untreated control animals were washed with M9
buffer to remove bacteria, and total RNA was extracted using the TRIzol
method. Total mRNA was subsequently enriched using the mirVana
miRNA isolation kit (Ambion) followed by poly-A capture. Library
construction and Illumina’s HiSeq 2000 technology sequencing was
performed following the manufacturer’s instructions. Approximately 12
million reads (100 bp length) for each sample were processed and aligned
using TopHat software to the C. elegans reference genome, version
WBcel235.74, to produce BAM files [Gene Expression Omnibus (GEO)
database reference GSE111654]. These BAM files were analyzed with the
SeqSolve NGS software (Integromics, S.L.), using a false discovery rate of
0.05 and filtering reads displaying multiple mapping sites. SeqSolve uses
Cufflinks and Cuffdiff (Trapnell et al., 2012) programs to perform
differential gene expression analyses between samples (P<0.005).
Expression values were normalized in FPKM (fragments per kilobase of
exon per million fragments mapped). Datasets of up- and downregulated
genes were generated, comparing the differential gene expression analyses
of two independent replicates (P<0.01 and P<0.05).
Cisplatin assay during larval development
A synchronized population of L1-arrested larvae was cultured on NGM
plates containing fresh OP50 and 0-200 µg/ml of cisplatin (Sigma). The
body length of ≥50 worms for each condition was measured at 48, 72 and
96 h at 20°C at the stereomicroscope using NIS-Elements 3.2 imaging
system. The subsequent analyses were performed with 60 µg/ml of cisplatin
in the same conditions except for assays containing daf-2(e1370) strain,
which were performed at 15°C, measuring the body length after 4 days of
incubation to avoid temperature-related developmental delay. Each assay
was done in duplicate, and at least two biological replicates were performed.
Nonparametric Student’s t-test (GraphPad Prism 5) was used to determine
the significance of differences in the mean.
Analysis of the effect of cisplatin in the germline
To analyze the effect of cisplatin on the germline, a synchronized population
of L4-stage animals grown in standard conditions (39 h at 20°C) was
transferred onto NGM plates containing 60 µg/ml cisplatin. After 24 h of
incubation at 20°C, worms were washed in PBS and germlines dissected in
worms anesthetized with 3 mM of levamisol in PBS, fixed with 4%
paraformaldehyde and stained with DAPI (0.6 µg/ml). These stained gonads
were photographed using a Nikon ECLIPSE TI-s inverted microscope. For
germ cell quantification in the proliferative region, the total number of cells
in a single z-stack within 50 µm of the distal end of the gonad was counted.
At least 15 germlines were counted for each experiment.
Brood size and unfertilized oocytes
To perform the self-fertilization assays, a synchronized population of L3-stage
worms was exposed to NGM plates, with addition of fresh OP50 and 0, 60 or
100 µg/ml of cisplatin for 24 h. A total of 12 worms from each condition were
selected onto fresh OP50 plates, counting the progeny and the number of
oocytes laid after 3 days. A similar protocol was performed for crossing
assays, where we used either a male-enriched population in the case of N2, or
the male–female population of the fog-2(oz40) allele. After 24 h of exposure
to cisplatin, a total of 12 genetic crosses were performed for each condition,
placing one hermaphrodite, or female in the case of fog-2(oz40), and four
males on freshOP50 plates, letting themmate and lay progeny for 3 days. This
experiment was performed in duplicate. A nonparametric Student’s t-test was
used to determine the significance of differences in the mean.
In vivo intracellular localization of DAF-16
To determine the subcellular localization of DAF-16, a synchronized L2-
stage population of worms carrying the DAF-16::GFP transgene (TJ356)
was transferred to M9 buffer containing 0, 90 or 180 µg/ml of cisplatin for
5 h at 20°C. Then, the worms were washed in M9 and mounted on a
microscope slide containing a 2% agar pad, using a drop of 3 mM
levamisole to anesthetize them. We quantified the DAF-16 subcellular
localization by considering as ‘nuclear’ worms showing a mainly nuclear
GFP accumulation along the whole body, as shown in Fig. 3B. A total of 50
worms were observed in each one of three independent replicates.
egl-p::GFP expression assays
To determine ectopic egl-1 expression, a synchronized L1-stage population
of egl-1p::GFP (WS1973) transgenic nematodes was grown on NGM plates
containing fresh OP50 and 60 μg/ml cisplatin plates for 24 h at 20°C. For in
vivo observation, worms were recovered with M9 buffer, washed and
mounted on a microscope slide containing a 2% agar pad, using a drop of
3 mM levamisole to anesthetize them. We used a Nikon ECLIPSE TI-s
inverted microscope to quantify the number of cells showing an ectopic GFP
signal. These experiments were performed three independent times.
RNAi and in vivo gst-4 expression assay
daf-16 and skn-1 RNAi clones used in this study were obtained from the
ORFeome library (Rual et al., 2004). RNAi by feeding was performed in
standard conditions, using NGM plates supplemented with 50 μg/μl
ampicillin, 12.5 μg/μl tetracycline and 3 mM IPTG. To analyze gst-4
induction, a synchronized L1-stage population of gst-4p::GFP reporter
strain was grown on plates containing the corresponding RNAi clone for
24 h at 20°C. Then, worms were transferred to new RNAi plates including 0
or 60 μg/ml cisplatin for 24 h. Then, worms were recovered with M9 buffer,
washed and mounted on a microscope slide containing a 2% agar pad, using
a drop of 3 mM levamisole to anesthetize them. A Nikon ECLIPSE TI-s
inverted microscope was used for in vivo observation, and image analysis
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was performed using ImageJ software. Average pixel intensity was
calculated by sampling 30 worms in each assay.
Southwestern blot analysis for Pt–DNA adducts
The southwestern blot analysis was performed using DNA extracted from a
synchronized population of C. elegans after 24 h incubation with or without
cisplatin. Genomic DNA (0.5 µg each sample) from C. elegans and from
NRK-52E rat cells (positive control) was isolated using the DNeasy Blood
and Tissue kit (Qiagen), denatured by heating (10 min, 95°C) and cooled on
ice. After adding 100 µl ice-cold ammonium acetate (2 M), the DNA was
transferred onto a nitrocellulose membrane, which was previously soaked in
1 M ammonium acetate. After washing (1 M ammonium acetate and water),
the membranewas baked for 2 h at 80°C before being blocked in 5% non-fat
milk in TBS/0.1% Tween 20 overnight at 4°C. Incubation with the primary
antibody directed against Pt–DNA adducts (1:2000; Abcam; ab103261) was
conducted for 1 h at room temperature. Visualization of the antibody signal
was done by chemiluminescence (Bio-Rad ChemiDoc Touch Imaging
System). Additionally, the membranewas stained withMethylene Blue (MP
Biomedicals) to ensure equal DNA loading.
Genetic interaction with gsr-1 assay
This procedure was performed as previously described (Stenvall et al., 2011).
Five L4 worms of the corresponding genotype were transferred to plates
containinggsr-1(RNAi)bacteria for 24 h at 20°C. Thenwormswere transferred
to new freshgsr-1(RNAi)plates, allowed to lay eggs for 12 h and then removed.
After 3 days at 20°C, larval arrest was analyzed only on day 2 plates.
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Oncologıá Médica (SEOM) grant for emerging research groups. F.J.G.-R. was the
recipient of a PFIS predoctoral fellowship from ISCIII. A.M.-V. was supported by a
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Tecnologıá ‘al extranjero’ fellowship (523048).
Data availability
Raw data and details of RNA-sequencing experiments are available at NCBI GEO,
with the reference GSE111654.
Supplementary information
Supplementary information available online at
http://dmm.biologists.org/lookup/doi/10.1242/dmm.033506.supplemental
References
Amable, L. (2016). Cisplatin resistance and opportunities for precision medicine.
Pharmacol. Res. 106, 27-36.
Anestål, K., Prast-Nielsen, S., Cenas, N. and Arnér, E. S. J. (2008). Cell death by
SecTRAPs:Thioredoxin reductaseasaprooxidant killerof cells.PLoSONE3, e1846.
Arnér, E. S. J. (2009). Focus on mammalian thioredoxin reductases—Important
selenoproteins with versatile functions. Biochim. Biophys. Acta 1790, 495-526.
Barsyte, D., Lovejoy, D. A. and Lithgow, G. J. (2001). Longevity and heavy metal
resistance in daf-2 and age-1 long-lived mutants of Caenorhabditis elegans.
FASEB J. 15, 627-634.
Blackwell, T. K., Steinbaugh, M. J., Hourihan, J. M., Ewald, C. Y. and Isik, M.
(2015). SKN-1/Nrf, stress responses, and aging in Caenorhabditis elegans. Free
Radic. Biol. Med. 88, 290-301.
Boyd, W. A., Crocker, T. L., Rodriguez, A. M., Leung, M. C. K., Wade Lehmann,
D., Freedman, J. H., Van Houten, B. and Meyer, J. N. (2010). Nucleotide
excision repair genes are expressed at low levels and are not detectably inducible
in Caenorhabditis elegans somatic tissues, but their function is required for normal
adult life after UVC exposure. Mutat. Res. 683, 57-67.
Bujan, L., Walschaerts, M., Moinard, N., Hennebicq, S., Saias, J., Brugnon, F.,
Auger, J., Berthaut, I., Szerman, E., Daudin, M. et al. (2013). Impact of
chemotherapy and radiotherapy for testicular germ cell tumors on
spermatogenesis and sperm DNA: a multicenter prospective study from the
CECOS network. Fertil. Steril. 100, 673-680.e2.
Cebula, M., Schmidt, E. E. and Arnér, E. S. J. (2015). TrxR1 as a potent regulator
of the Nrf2-Keap1 response system. Antioxid Redox Signal. 23, 823-853.
Chang, E. M., Lim, E., Yoon, S., Jeong, K., Bae, S., Lee, D. R., Yoon, T. K. and
Choi, Y. (2015). Cisplatin induces overactivation of the dormant primordial follicle
through PTEN/AKT/FOXO3α pathway which leads to loss of ovarian reserve in
mice. PLoS ONE 10, 1-16.
Collis, S. J., Barber, L. J., Ward, J. D., Martin, J. S. and Boulton, S. J. (2006). C.
elegans FANCD2 responds to replication stress and functions in interstrand cross-
link repair. DNA Repair 5, 1398-1406.
Dasari, S. and Bernard Tchounwou, P., (2014). Cisplatin in cancer therapy:
Molecular mechanisms of action. Eur. J. Pharmacol. 740, 364-378.
Dilruba, S. and Kalayda, G. V. (2016). Platinum-based drugs: past, present and
future. Cancer Chemother. Pharmacol. 77, 1103-1124.
Ellis, R. and Schedl, T. (2007). Sex determination in the germ line. WormBook
(ed. The C. elegans Research Community). WormBook, doi/10.1895/
wormbook.1.82.2.
Ermolaeva, M. A. and Schumacher, B. (2013). The innate immune system as
mediator of systemic DNA damage responses. Commun. Integr. Biol. 6, e26926.
Fernandez De Mattos, S., Clardy, J. and Lam, E. W.-F. (2008). FOXO3a mediates
the cytotoxic effects of cisplatin in colon cancer cells. Mol. Cancer Ther. 7,
3237-3246.
Friedland, A. E., Tzur, Y. B., Esvelt, K. M., Colaiácovo, M. P., Church, G. M. and
Calarco, J. A. (2013). Heritable genome editing in C. elegans via a CRISPR-Cas9
system. Nat. Methods 10, 741-743.
Galanski, M. (2006). Recent developments in the field of anticancer platinum
complexes. Recent Patents Anticancer Drug Discov. 1, 285-295.
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A.,
Castedo, M. and Kroemer, G. (2014). Systems biology of cisplatin resistance:
past, present and future. Cell Death Dis. 5, e1257.
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